Posted On: 11/18/2016 4:03:50 PM
Post# of 72443
Interesting, Green. Looks like there were severe safety issues as well as concerns about efficacy.
http://www.bioworld.com/content/fda-rejects-a...-partner-0
Quote:
Arpida's shares took a 54 percent hit in November after an FDA analysis of Phase III data of iclaprim raised significant concerns about its efficacy and safety, with three deaths suspected of being related to the drug. (See BioWorld Today, Nov. 19, 2008.)
The analysis showed that iclaprim was less effective than New York-based Pfizer Inc.'s Zyvox (linezolid) , which conflicted with the results released by Arpida in July 2007 and December 2006.
http://www.bioworld.com/content/fda-rejects-a...-partner-0
(2)
(0)Scroll down for more posts ▼
